摘要 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R1, R2, R3 and R4 are as described in this application, and methods of using the compounds in the treatment of cancer.; |
主权项 |
1. A compound of Formula I: wherein: W is selected from the group a) H, b) C1-6-alkyl that optionally includes 1-3 deuterium atoms, c) C1-6-alkyl that optionally may be substituted with SO2R5 and OR5 Y is C1-6-alkyl that optionally may be substituted with OR5; Z is N; R1 is selected from the group a) C1-6-alkyl that optionally may be substituted with SO2R5, b) C3-7-cycloalkyl, c) heterocyclic, and d) aryl; R2 is C1-6-alkyl that optionally may be substituted with NHC(O)R6, NHSO2R5, NHCOOR6 and NHR6; R3 and R4 may be the same or different and each is independently selected from the group a) H, and b) C1-6-alkyl; R5 is selected from the group a) H, b) C1-6-alkyl, c) NR7R8, and d) aryl; R6 is selected from the group a) H b) aryl that optionally may be substituted with C1-6-alkyl, OR5, halogen, C(O)OR5, C(O)NR7R8, aryl, heterocyclyl, C(O)R9, SO2R5, cyano and CF3, c) C1-6-alkyl that optionally may be substituted with CF3, SO2R5 and aryl that optionally may be substituted with C1-6-alkyl and halogen, d) OR5, e) NR7R8, f) heteroaryl that optionally may be substituted with C1-6-alkyl, OR5, halogen, aryl and oxo, and g) heterocyclyl; R7 and R8 may be the same or different and each is independently selected from the group a) H, b) C1-6-alkyl, and c) aryl; and R9 is selected from the group a) C1-6-alkyl, and b) aryl; or a pharmaceutically acceptable salt thereof. |